Raymond James Financial Services Advisors, Inc. Fennec Pharmaceuticals Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$6.21 - $8.68 $175,898 - $245,861	-28,325 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$5.99 - $8.55 $19,916 - $28,428	3,325 Added 13.3%	28,325 $211,000
Q3 2020 Nov 04, 2020	BUY	$5.19 - $10.17 $129,750 - $254,250	25,000 New	25,000 $152,000

Others Institutions Holding FENC

# of Institutions

Shares Held

14.9M

Call Options Held

10K

Put Options Held

83.8K

Southpoint Capital Advisors LP New York, NY

4.08M
Shares

$25 Million
0.57% of portfolio
Sonic Gp LLC Honolulu, HI

2.41M
Shares

$14.8 Million
27.51% of portfolio
Solas Capital Management, LLC Darien, CT

1.92M
Shares

$11.8 Million
7.68% of portfolio
Dg Capital Management, LLC New York, NY

1.52M
Shares

$9.35 Million
4.41% of portfolio
Black Rock Inc. New York, NY

1.19M
Shares

$7.29 Million
0.0% of portfolio

View Full List

About FENNEC PHARMACEUTICALS INC.

Ticker FENC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,067,300
Market Cap $160M
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...

More about FENC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account